Atai Beckley Inc.
ATAI
NASDAQ·Healthcare·Biotechnology·Mkt cap $2.7B
$7.39
▲ +0.68%
P/E
-3.38
Mkt Cap
$2.7B
52-Wk Range
$3.27–$7.45
52-Week Range
$3.27 - $7.45
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 63.5% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- First-mover advantage in psychedelic-assisted mental health treatments
- Diversified pipeline reducing development risk across multiple compounds
- Strategic partnerships with leading research institutions and biotech companies
- Visionary leadership and significant capital resources for R&D acceleration
Bear Case
1 risk
- Above-average volatility (beta 1.6).
Growth
Revenue decline expected
Regulatory approval of psychedelic therapies expanding market opportunities
Value
Trading at 0.0x Healthcare Distribution peers — a discount despite the growth profile.
Momentum
Hot
+94.0% over 3m
Quality
Excellent
Emerging growth company (73% revenue growth). Early stage with higher risk.
Dividend
None
No dividend
Smart-money signal
Who's buying ATAI right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 11, 2026
AUG 11, 2026
Reported EPS of -$0.09 vs -$0.11 consensus (+15.6% surprise). Revenue of $1.7M vs $430.4K expected (+295.9%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+15.6%
Revenue trend · last 8Q
—
—
—
+163%
+1773%
—
-39%
+137%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$40.0K
-$5.0K
$1.6M
$719.0K
$749.0K
$1.1M
$954.0K
$1.7M
Margins · last 8Q
Gross
87.4%
Profit
-1908.7%
Wall Street consensus
7 analysts · 14% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
14%
Hold
86%
Sell
0%
Median Price Target
—
Latest: Deutsche Bank · Aug 12, 2026
vs Industry
How ATAI stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related